Company Overview

Charlotte’s Web Holdings, Inc. is a U.S.-based wellness company focused on hemp-derived cannabidiol (CBD) products and botanical wellness supplements. The company operates within the consumer health, nutraceutical, and hemp wellness industries, manufacturing and marketing CBD oils, gummies, capsules, topicals, and pet wellness products. Its primary revenue drivers come from branded CBD wellness products sold through e-commerce channels, food and drug retailers, health practitioners, and specialty retail partners. The company primarily serves health-conscious consumers seeking hemp-based wellness products for sleep, stress management, recovery, and overall wellness support.

Charlotte’s Web traces its origins to the Stanley Brothers’ development of a proprietary hemp cultivar associated with pediatric epilepsy advocacy involving Charlotte Figi, for whom the brand was named. The company expanded from a niche hemp extract producer into one of the more recognizable CBD consumer brands in North America following the passage of the 2018 U.S. Farm Bill, which federally legalized hemp cultivation under defined THC limits. Its strategic positioning has centered on vertically integrated hemp sourcing, proprietary genetics, large-scale cultivation capabilities, and brand recognition within the regulated hemp wellness category.

Business Operations

The company operates primarily through its Consumer Products business, which includes ingestible CBD products, topical formulations, and pet wellness offerings marketed under the Charlotte’s Web brand. Revenue is generated through direct-to-consumer online sales, business-to-business wholesale distribution, and retail partnerships across natural grocery, pharmacy, and wellness channels. The company has historically emphasized vertically integrated operations, including hemp cultivation, extraction, formulation, manufacturing oversight, and product testing. Public filings and company disclosures indicate operations concentrated in the United States, with cultivation and production assets historically located in Colorado and other U.S. agricultural regions.

Charlotte’s Web has maintained partnerships with retailers, healthcare practitioners, and research organizations focused on cannabinoid science and botanical wellness. The company has also expanded into botanical supplement categories beyond CBD through acquisitions and brand extensions. Its controlled assets include proprietary hemp genetics, extraction capabilities, intellectual property related to hemp cultivation and formulations, and a broad consumer distribution network. Data regarding certain international joint ventures and inactive partnerships is inconclusive based on available public sources.

Strategic Position & Investments

Charlotte’s Web has pursued a strategy centered on brand leadership in the hemp-derived wellness sector, product diversification, and regulatory positioning ahead of broader cannabinoid market normalization in the United States. Growth initiatives have included expanding retail distribution, increasing product offerings in sleep, cognition, and functional wellness categories, and investing in research-backed formulations. The company has publicly emphasized compliance standards, product quality testing, and advocacy for clearer federal CBD regulation as differentiators within a fragmented industry.

A notable strategic transaction was the acquisition of Abacus Health Products, Inc., which expanded the company’s topical wellness portfolio and retail penetration. Charlotte’s Web has also invested in research collaborations involving cannabinoid science and has explored emerging wellness sectors tied to functional botanicals and nutraceutical products. The company’s broader strategy has reflected efforts to stabilize revenue amid industry-wide pricing pressure, regulatory uncertainty, and evolving consumer demand in the CBD market.

Geographic Footprint

Charlotte’s Web is headquartered in Louisville, Colorado, and its primary commercial operations are concentrated in the United States. The company distributes products nationally through e-commerce and retail partnerships spanning natural food chains, pharmacies, mass retailers, and wellness-focused outlets. Its cultivation and manufacturing footprint has historically included operations in Colorado and additional agricultural sourcing relationships across U.S. hemp-producing regions.

While the company has pursued opportunities outside the United States, its operational and revenue concentration remains predominantly North American. Public disclosures indicate selective international market activity and export capabilities, though the scale of international revenue contribution is limited relative to domestic operations. The company’s market presence is strongest in the U.S. consumer CBD wellness category, where it competes with both large consumer packaged goods entrants and specialized cannabinoid brands.

Leadership & Governance

Charlotte’s Web was founded by the Stanley Brothers, whose hemp cultivation and cannabinoid research efforts formed the foundation of the brand. The company operates under a public-company governance structure with executive leadership focused on operational efficiency, regulatory engagement, and long-term brand development in the wellness sector. Management commentary in public filings and investor communications has emphasized disciplined cost management, science-backed product development, and expansion of consumer trust through compliance and quality assurance initiatives.

Key executives and leadership figures have included:

• Bill Morachnick – Chief Executive Officer
• Russ Hammer – Chief Financial Officer
• Jared Stanley – Co-Founder
• Joel Stanley – Co-Founder and Chairman
• Jacques Tortoroli – Former Chief Executive Officer and Board Member

Leadership composition and executive roles have changed periodically as the company adapted to evolving market conditions in the CBD industry. Information above reflects publicly available company disclosures and securities filings available through Canadian and U.S. regulatory reporting systems.